Prevalence of headache in Europe: a review for the Eurolight project

Overview of attention for article published in The Journal of Headache and Pain, May 2010

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#40 of 1,555)
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

news: 18 news outlets
blogs: 1 blog
policy: 1 policy source
twitter: 1 X user

facebook: 1 Facebook page
wikipedia: 3 Wikipedia pages
video: 1 YouTube creator

Citations

dimensions_citation: 417 Dimensions

Readers on

mendeley: 408 Mendeley

Summary News Blogs Policy documents X Facebook Wikipedia YouTube Dimensions citations

So far, Altmetric has seen 21 news stories from 18 outlets.

News story from Finanz Nachrichten on Thursday 12 March 2020

Finanz Nachrichten, 12 Mar 2020

Avis favorable de lInstitut national pour lexcellence clinique (NICE) pour le premier traitement anti-PRGC de la migraine : AJOVY®▼ (fremanezumab)

Business Wire, 12 Mar 2020

TEL AVIV, Israël--( BUSINESS WIRE )--Teva Pharmaceutical Europe BV, une filiale de Teva Pharmaceutical Industries Ltd.

Positive Empfehlung des NICE für die erste, gegen das CGRP gerichtete Migränetherapie: AJOVY®▼ (Fremanezumab)

Yahoo! Finance USA, 12 Mar 2020

Teva Pharmaceutical Europe BV, eine Tochtergesellschaft von Teva Pharmaceutical Industries Ltd.

Positive Empfehlung des NICE für die erste, gegen das CGRP gerichtete Migränetherapie: AJOVY®▼ (Fremanezumab)

Business Wire, 12 Mar 2020

TEL AVIV, Israel--( BUSINESS WIRE )--Teva Pharmaceutical Europe BV, eine Tochtergesellschaft von Teva Pharmaceutical Industries…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 17 additional news stories.